07:43 AM EDT, 09/29/2025 (MT Newswires) -- Applied Therapeutics ( APLT ) said Monday that a path forward for its new drug application for govorestat to treat Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency has not been determined.

The company said it completed a meeting with the US Food and Drug Administration to discuss the potential submission in Q3.

Applied Therapeutics ( APLT ) said it is waiting for the official meeting minutes from the FDA to decide on the next steps.

Charcot-Marie-Tooth Sorbitol Dehydrogenase deficiency is a genetic metabolic disease.

Shares of Applied Therapeutics ( APLT ) were down more than 60% in recent Monday premarket activity.

Price: 0.49, Change: -0.75, Percent Change: -60.51